Selecting Triple Negative Breast Cancer Patients for Immunotherapy.
Immunotherapy
Neoadjuvant
Pembrolizumab
Triple negative breast cancer
Journal
Surgical oncology clinics of North America
ISSN: 1558-5042
Titre abrégé: Surg Oncol Clin N Am
Pays: United States
ID NLM: 9211789
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
medline:
18
9
2023
pubmed:
16
9
2023
entrez:
15
9
2023
Statut:
ppublish
Résumé
The approval of preoperative immunotherapy combined with chemotherapy is a practice-changing advance for patients with early-stage triple-negative breast cancer. The optimal patient selection requires careful attention to staging and balancing potential risks with expected benefits, particularly as it relates to immune-related adverse events.
Identifiants
pubmed: 37714640
pii: S1055-3207(23)00043-1
doi: 10.1016/j.soc.2023.05.005
pii:
doi:
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
733-745Subventions
Organisme : NCI NIH HHS
ID : K08 CA259533
Pays : United States
Informations de copyright
Copyright © 2023 Elsevier Inc. All rights reserved.